Precision BioSciences, Inc. (DTIL)
$1.53
Rating:
Recommendation:
-
| Symbol | DTIL |
|---|---|
| Price | $1.53 |
| Beta | 1.813 |
| Volume Avg. | 2.52M |
| Market Cap | 114.474M |
| Shares () | - |
| 52 Week Range | 1.11-14.38 |
| 1y Target Est | - |
| DCF Unlevered | DTIL DCF -> | |
|---|---|---|
| DCF Levered | DTIL LDCF -> | |
| ROE | -44.19% | Strong Sell |
| ROA | -22.10% | Sell |
| Operating Margin | - | |
| Debt / Equity | 160.34% | Buy |
| P/E | - | |
| P/B | 1.34 | Strong Buy |
Latest DTIL news
About
Download (Excel)Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.